Abstract
Introduction
The overall survival (OS) of metastatic castration-resistant prostate cancer (mCRPC)
patients has improved since 2011 with the use of novel hormonal agents (NHAs). The
incidence of brain metastases (mets) has been reported to increase since 2004 with
the use of docetaxel, but not the incidence of visceral mets. Our objective was to
study whether the use of NHAs increases the risk of developing visceral or brain mets
(VBMs).
Patients and Methods
mCRPC patients with mets limited to bone (bmCRPC), treated at Tours University Hospital
between 2007 and 2015, were included retrospectively. The primary endpoint was to
determine whether treatment with NHAs was associated with an increased incidence of
VBMs. Secondary endpoints included the search for putative predictive factors to develop
VBMs.
Results
On 187 bmCRPC patients included, 65 developed VBMs. VBM incidence increased in bmCRPC
patients alive after 2011, compared to patients who died before (39.7 vs. 24.6%, P = .04). Meanwhile, their median OS increased from 16.3 months to 28.5 months (P = .01). The longer was the treatment with NHAs, the lower was the risk of VBMs (HR = 0.96,
95% CI [0.94; 0.99]), whereas age < 70 years (HR = 3.33, 95% CI [1.50; 7.40]) and
low PSA level at diagnosis (HR = 1.58, 95% CI [1.16; 2.15]) increased this risk.
Conclusion
Though retrospective, our results showed an increased incidence of VBMs in bmCRPC
patients after 2011. However, this was not associated with NHA exposure duration.
The role of NHA exposure remains unclear and needs further investigation.
Keywords
Abbreviations:
bmCRPC (Bone metastatic castration resistant prostate cancer), CNIL (« Commission Nationale de l'Informatique et des Libertés »), ISUP (International society of urological pathology), mCRPC (Metastatic castration resistant prostate cancer), mets (Metastases), NHA (Novel hormonal agent), OS (Overall survival), PCWG2 (Prostate cancer clinical trials working group), PSA (Prostate-specific antigen), VBM (Visceral and/or brain metastases), wo (Without)To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Genitourinary CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Epidemiology of prostate cancer.World J Oncol. 2019; 10: 63-89https://doi.org/10.14740/wjon1191
- Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.N Engl J Med. 2004; 351: 1502-1512https://doi.org/10.1056/NEJMoa040720
- Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients.Hum Pathol. 2000; 31: 578-583https://doi.org/10.1053/hp.2000.6698
- Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.N Engl J Med. 1995; 332: 1393-1398https://doi.org/10.1056/NEJM199505253322101
- Enzalutamide in metastatic prostate cancer before chemotherapy.N Engl J Med. 2014; 371: 424-433https://doi.org/10.1056/NEJMoa1405095
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.Lancet Oncol. 2015; 16: 152-160https://doi.org/10.1016/S1470-2045(14)71205-7
- Brain metastasis from prostate carcinoma: the M. D. Anderson Cancer Center experience.Cancer. 2003; 98: 363-368https://doi.org/10.1002/cncr.11522
- Impact of the site of metastases on survival in patients with metastatic prostate cancer.Eur Urol. 2015; 68: 325-334https://doi.org/10.1016/j.eururo.2014.07.020
- Abiraterone and increased survival in metastatic prostate cancer.N Engl J Med. 2011; 364: 1995-2005https://doi.org/10.1056/NEJMoa1014618
- Increased survival with enzalutamide in prostate cancer after chemotherapy.N Engl J Med. 2012; 367: 1187-1197https://doi.org/10.1056/NEJMoa1207506
- Frequency of brain metastases from prostate cancer: an 18-year single-institution experience.J Neurooncol. 2013; 111: 163-167https://doi.org/10.1007/s11060-012-0994-1
- Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer.J Clin Oncol. 2016; 34: 1652-1659https://doi.org/10.1200/JCO.2015.65.7270
- In men with castration-resistant prostate cancer, visceral metastases predict shorter overall survival: what predicts visceral metastases? Results from the SEARCH database.Eur Urol Focus. 2017; 3: 480-486https://doi.org/10.1016/j.euf.2016.08.007
- Prognostic significance of sites of visceral metastatic disease in prostate cancer: a population-based study of 12,180 patients.Clin Genitourin Cancer. 2019; 17: 260-267https://doi.org/10.1016/j.clgc.2019.03.020
- Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.J Clin Oncol. 2013; 31: 1748-1757https://doi.org/10.1200/JCO.2012.43.1882
- Is prostate cancer changing?: evolving patterns of metastatic castration-resistant prostate cancer.Cancer. 2014; 120: 833-839https://doi.org/10.1002/cncr.28494
- Contemporary incidence and cancer control outcomes of primary neuroendocrine prostate cancer: a SEER database analysis.Clin Genitourin Cancer. 2017; 15: e793-e800https://doi.org/10.1016/j.clgc.2017.04.006
- Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.J Clin Oncol. 2008; 26: 1148-1159https://doi.org/10.1200/JCO.2007.12.4487
- Evolving Natural History of Metastatic Prostate Cancer.Cureus. 2020; 12 (PMID: 33329980; PMCID: PMC7735525): e11484https://doi.org/10.7759/cureus.11484
- Clinical and molecular features of treatment-related neuroendocrine prostate cancer.Int J Urol. 2018; 25: 345-351https://doi.org/10.1111/iju.13526
- Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study.J Clin Oncol. 2018; 36: 2492-2503https://doi.org/10.1200/JCO.2017.77.6880
- Morphologic, molecular and clinical features of aggressive variant prostate cancer.Cells. 2020; 9: 1073https://doi.org/10.3390/cells9051073
- The hallmarks of castration-resistant prostate cancers.Cancer Treat Rev. 2015; 41: 588-597https://doi.org/10.1016/j.ctrv.2015.05.003
- Androgen receptor-related micro RNAs in prostate cancer and their role in antiandrogen drug resistance.J Cell Physiol. 2020; 235: 3222-3234https://doi.org/10.1002/jcp.29275
- Disrupting androgen receptor signaling induces snail-mediated epithelial-mesenchymal plasticity in prostate cancer.Cancer Res. 2017; 77: 3101-3112https://doi.org/10.1158/0008-5472.CAN-16-2169
- Identification of key genes and multiple molecular pathways of metastatic process in prostate cancer.PeerJ. 2019; 7: e7899https://doi.org/10.7717/peerj.7899
- A new model of multi-visceral and bone metastatic prostate cancer with perivascular niche targeting by a novel endothelial specific adenoviral vector.Oncotarget. 2017; 8: 12272-12289https://doi.org/10.18632/oncotarget.14699
- Brain metastases from prostate cancer: an 11-year analysis in the MRI era with emphasis on imaging characteristics, incidence, and prognosis.J Neuroimaging. 2014; 24: 161-166https://doi.org/10.1111/j.1552-6569.2012.00767.x
- Prostate adenocarcinoma with brain metastasis: a surveillance, epidemiology, and end results database analysis 2010-2015.Med Sci Monit. 2021; 27https://doi.org/10.12659/MSM.930064
- Treatment and survival outcomes in young men diagnosed with prostate cancer: a Population-based Cohort Study.Cancer. 2009; 115: 2863-2871https://doi.org/10.1002/cncr.24324
Article info
Publication history
Published online: April 21, 2022
Accepted:
April 14,
2022
Received in revised form:
April 11,
2022
Received:
December 29,
2021
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
